Slides
Page 1
1 1 PI Industries Ltd. Investor Presentation Q3 FY26 Result Certain statements made in this presentation may not be based on historical information or facts and may be “ forward looking statements, ” including those relating to general business plans and strategy of PI Industries Limited (“ PIIL") (including its subsidiaries) , its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment . Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause the actual results to differ materially from those contemplated by the relevant forward - looking statements , which are based upon what management of the Company believes are reasonable assumptions . This could also differ due to a number of other factors, including future changes or developments in PIIL's business, its competitive environment, its ability to implement its strategies and initiatives and respond to technological changes . This presentation does not constitute a prospectus, offering circular or offering memorandum or an offer, or a solicitation of any offer, to purchase or sell, any shares and should not be considered as a recommendation that any investor should subscribe for or purchase any of PIIL's shares . Neither this presentation nor any other documentation or information (or any part thereof) delivered or supplied under or in relation to the shares shall be deemed to constitute an offer of or an invitation by or on behalf of PIIL . This presentation should be read in conjunction with the financial statements included herein . PIIL, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein . The information contained in this presentation, unless otherwise specified is only current as of the date of this presentation . PIIL assumes no responsibility to publicly amend, modify or revise any forward - looking statements, on the basis of any subsequent development, information or events, or otherwise . Unless otherwise stated in this document, the information contained herein is based on management information and estimates . The information contained herein is subject to change without notice and past performance is not indicative of future results . PIIL may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes . This presentation may not be copied and disseminated in any manner . PIIL will not be in any way responsible for any action taken based on such forward - looking statements . THE INFORMATION PRESENTED HERE IS NOT AN OFFER OR SOLICITATION OF ANY OFFER TO PURCHASE OR SELL ANY EQUITY SHARES OR ANY OTHER SECURITY OF PI INDUSTRIES LTD. CDR India Siddharth Rangnekar siddharth@cdr - india.com Nishid Solanki nishid@cdr - india.com Tel: +91 22 6645 1221 /1209 Fax: +91 22 6645 1213 PI Industries Limited Rajnish Sarna r.sarna@piind.com Sanjay Agarwal sanjay.agarwal@piind.com Tel: +91 22 6266 5600 Fax: +91 22 6266 5765
Page 2
2 • Consolidated Financial Performance • Key Updates • ESG Credentials • Rewards & Recognition • Business Model and Strategy AGENDA
Page 3
Near - Term Demand Softness..... Underlying Fundamentals Remain Strong Revenue EBITDA Q3FY26 INR Mn 13,757 3,027 Commercialized 5 new products in Exports and 4 in Domestic Agri Brands Positive traction in Pharma ~50% Y - o - Y 9MFY26 revenue growth Investing for growth Capex spend of INR 7,225 Mn in 9MFY26 *Q3 FY26 and 9M FY26 PAT includes exceptional Items New products in Agchem Exports grew ~10% Y - o - Y in 9MFY26 28% 41% PAT* 3,113 16% 9MFY26 51,485 13,680 17% 21% 11,206 16% 9M: 3 - year CAGR 1% 5% 6% Consolidated Financials Received Regulatory approval for Harpin αβ in India & Obrona , a biochemical pesticide in the US 3
Page 4
Q3 Performance Reflects Customer Delivery Phasing and Market Conditions … Preserved Healthy Margins Amid Volume Timing • ~32% decline in Agchem Exports (Volume down ~ 29 %) in line with customer delivery schedule . • Domestic revenue softened by ~8% Y - o - Y (Volume down ~2%) : o Lower farmer demand for high - value products; o Erratic monsoon and softer commodity realisations impacted key crops e.g. chilli , grapes, etc.; o Regulatory transitions in Biologicals towards normalization. • Pharma 1 revenue contracted by 6% Y - o - Y due to deferment of supply schedules to Q4FY26. Pharma revenue contributes ~5% of Exports revenue . • Favorable product mix and cost discipline driving Gross margin improvement. • Overheads increase comprising strategic development of newer businesses and promotion of new products (6%), offset by effective cost control in existing businesses. • Net Profit for Q3FY26 and 9MFY26 includes exceptional income on account of writeback of contingent consideration of INR 1260 Mn partially offset by additional provisioning of retirement benefits as per New labor code to the tune of INR 209 Mn. • The Board has approved interim dividend for FY25 - 26 of Rs 5.00 per share. INR Mn Q3FY25 Q3FY26 % YOY Revenue 19,008 13,757 (28)% Gross Margin 53% 59% 631 bps Overheads 4,898 5,095 4% EBITDA 5,122 3,027 (41)% EBITDA margin % 27% 22% (495) Bps Net Profit 3,727 3,113 (16)% 31.0% 7.9 % 16.5 % 40.9 % Exports Domestic Q3FY25 Q3FY26 EBITDA PAT Q3FY25 Q3FY26 16,202 2,806 5,122 3,727 11,173 2,584 3,027 3 ,113 INR Mn INR Mn 1 Pharma: PI Health Sciences Ltd. ( “ PIHSL ” ) Consolidated including overseas subsidiaries 4
Page 5
Resilient Margins and Portfolio Strength Across 9MFY26 • Agchem Exports muted by 20% Y - o - Y (Volume down ~16%) due to high base effect ( Y - o - Y growth: 9M FY24 - 22%, 9M FY25 - 9%), partially offset by growth in new products 10% Y - o - Y o 5 molecules commercialised in 9MFY26; o Commercialized differentiated technologies of Flow and Vapor Phase chemistry. • Domestic revenue decline by ~6% Y - o - Y (Volume down ~2%) due to elevated channel inventories, adverse weather conditions and lower crop prices o 4 products commercialised in 9MFY26; o 2 more products to be launched in Q4FY26. • Pharma 1 revenue grew 50% Y - o - Y and contributing ~5% of total Exports revenue. Onboarded new customers to portfolio expanding opportunity funnel. • Received Regulatory approval for Harpin αβ in India and a biochemical pesticide in US. • EBITDA margin sustained at 27%: Favorable product mix backed by strong operating efficiencies. INR Mn 9MFY25 9MFY26 % YOY Revenue 61,907 51,485 (17)% Gross Margin 52% 58% 573 bps Overheads 14,992 16,124 8% EBITDA 17,264 13,680 (21)% EBITDA margin % 28% 27% (132) Bps Net Profit 13,297 11,206 (16)% 19.1% 6.1 % 15.7 % 20.8 % Exports Domestic 9MFY25 9MFY26 EBITDA PAT 9MFY25 9MFY26 51,306 10,601 17,264 13,297 41,532 9,953 13,680 1 1,206 INR Mn INR Mn 5 1 Pharma: PI Health Sciences Ltd. ( “ PIHSL ” ) Consolidated including overseas subsidiaries
Page 6
Strong, Debt Free Balance Sheet Enabling Growth Investment • Surplus cash net of Debt is INR 35,066 Mn enabling the company to pursue accelerated growth. • Total capex for 9M FY26 stood at INR 7,225 Mn (9M FY25: INR 6,485 Mn), reflecting continued investment in manufacturing capabilities and R&D infrastructure. • Trade working capital in terms of Days of Sales at 139 days vs 115 days of Sep - 25 due to inventory build - up and calibrated credit extension in line with prevailing liquidity constraints. 2 ROCE computed excluding Cash, Bank & Investments 59 69 Inventory DIO Trade Receivables DSO 120 130 64 60 Payables DPO 115 139 NWC Days Q2FY26 Q3FY26 INR Mn Dec-24 Mar-25 Dec-25 Shareholders Fund 98,660 1,01,570 1,11,458 Non Current Liabilities 3,406 3,920 3,839 Short term debt 305 337 639 Other Current Liabilities 6,660 4,838 5,901 Total 1,09,031 1,10,665 1,21,837 Fixed Asset Inc. Goodwill 45,629 47,589 52,640 Non current investments & other assets 2,860 5,656 3,079 Working Capital 15,422 16,063 26,156 Cash, Bank & Investments 41,583 37,594 35,654 Other assets 3,537 3,763 4,308 Total 1,09,031 1,10,665 1,21,837 Key Ratios (%) Annualised Debt/ Equity Ratio 0.01 0.01 0.02 Net Sales to Net Fixed Assets 2.05 1.90 1.47 ROCE 2 32.5% 28.9% 20.3% 6
Page 7
Innovation Pipeline Delivering Differentiated, High - Value Crop Solutions … strengthening market position 7 Dorito ® Pressedo ® Osheen Ultra ® Claret ® Unique combination of systemic and contact insecticide Eketsu 1 st 3 - way Rice Herbicide Kadett ® Combination Fungicide Pilin ® Bio - fungicide with Novel Mode Of Action Aminogrow Activ Amino acid & Peptides product Campana New systematic insecticide Solju Gr & Solju SP Kaprigin ® FY25 BYROCK ® Vachan RICE HORTICULTURE CHILLI WHEAT CORN SUGARCANE Crop Solutions FY24 Alcor ® S ystemic herbicide for management of ALS resistance weeds FY26 Comet ® Post emergent herbicide for control of grasses Robust pipeline of 20+ products at different stages of development and registration Uranus ® For Mites control Broad spectrum novel insecticide For sucking pest control Unique microbial biofertiliser Broad spectrum insecticide Fungicide Organic Fertiliser Insecticide for Leps management 2 more innovative products to be launched in FY26 Fixit ® Herbicide for Rice weeds control COTTON SOYBEAN
Page 8
PI Mitra Kisan: Strengthening Farmer Engagement Through Digital Platform 8 Mobile App launched Pan India Outreach Multilingual capability Scan To Earn • Scan the QR code on bottle cap or pouch to earn monetary rewards • Rewards can be instantly redeemed as cashback by farmer via UPI • Information about the product ’ s genuity FEEDBACK: Voice of Farmers • Easy to use: The app is simple to understand, making product scanning and loyalty point tracking convenient. • Real value: Loyalty benefits and rewards are useful and motivate us to stay connected with the company. • Product authenticity: The app helps us verify that the product we are buying is genuine, giving confidence and peace of mind. Product Information Information related to product features and benefits, dosage, application, Do ’ s & Don'ts. Complaint Resolution Complaints regarding app functionality can be registered on the app, with a resolution TAT of 24 - 48 hours APP FEATURES Rewards Chance for lucky customers to win a Bumper prize on the 1 st product scan
Page 9
INR Mn 9MFY25 9MFY26 % YOY Revenue 1,301 1957 50% PBT (1,827) (485)* 73% INR Mn Q3FY25 Q3FY26 % YOY Revenue 637 599 (6)% PBT (562) 750* - Pharma Platform Scaling with New Customer wins in CRDMO Portfolio … • Onboarded new customers over the last 12 months, including several strategic accounts and large pharma customers supporting mid - to long - term growth. • 9MFY26: 50% Y - o - Y revenue growth. • One - off processing related cost and product mix. • Higher overheads due to investments in capability building, people and processes. • Capex ~INR 616 Mn (9MFY25 ~INR 954 Mn). * Post intercompany eliminations and includes exceptional income on account of writeback of contingent consideration of INR 1,260 Mn Expanding & enhancing GMP site in Lodi, Italy; non - GMP in India Building relationships with Biotech & Big Pharma through Global Business Development Strengthening the Regulatory capabilities to be Best - in - Class Leveraging PI ’ s Scientific & Business Process Capabilities for Pharma Slowdown in biotech funding and geopolitical challenges Way Ahead 9 INR Mn 253 411 637 1301 723 634 599 1957 Q1 Q2 Q3 9M Revenue FY25 FY26
Page 10
Classification | PI Confidential Classification | PI Confidential Biologicals Positioned for Long - Term Global Growth … .. Regulatory Pathways and Market Trials Progressing as per plan 10 • Investments made in product development in the US, Brazil and Mexico • Expansion of distribution network and user base for seed treatment brands Saori ® and Teikko ® in Brazil • Unique biological solution for nematodes launched in Mexico (brand name Shanema ® ) • New registration filed for Bio - nematicide in the US; Commercial label approval for Obrona ® in California, US • Received regulatory approval for launch of Harpin αβ in India • Commissioned research center for plant systems to support global biologicals research • Seaweed Extract Platform • Suppression of broad - spectrum diseases and nematodes • 2 nd Gen Recombinant Harpin αβ Peptide Platform • Commercialized in more than 25 Countries • Microbials and Plant Extracts Platform • Nutrient Efficiency Brand • Soil Nutrition Brand • 3 rd Gen PRETec Peptide Platform • Broad Spectrum Disease and Nematode Management Solutions • Biocontrol Brands Biostimulants Soil & Nutrition Solutions Biocontrol Continued investments in market and product development in focused geographies Building relationships with distributors in US, Brazil and other markets Investing to upgrade capabilities in R&D in the US and India Filing label expansion of peptides in the US, Brazil & Mexico Way Ahead Building global product portfolio and brands Global Biologicals (Ex - India) annualized revenue in the range ~ USD 13 Mn with healthy gross margin upwards of 60% , expected to grow in double digits
Page 11
Classification | PI Confidential Among the Top ESG Performers Globally … ...ranked among the Top 2 percentile of S&P global ESG rated companies 11 Carbon emissions intensity in terms of revenue from operations (INR million) Water intensity in terms of revenue from operations (INR million) Chemical Oxygen Demand (in MT) 3.29 3.37 2.75 2.36 1.99 1.94 FY21 FY22 FY23 FY24 FY25 FY26 Q3 17.24 17.35 14.79 8.19 8.23 8.39 FY21 FY22 FY23 FY24 FY25 FY26 YTM Q3 41.1 43.90 33.20 23.40 23.46 FY21 FY22 FY23 FY24 FY25 Key Highlights* SDG Alignment Environment – Climate change 70% of enrolled youth placed through skill development initiatives 503,000 + healthcare beneficiaries through Mobile Health units and 1 5 7 ,000+ students impacted through various initiatives since FY21 Increased employees ’ average training hours per FTE by 53% from FY21 Increased women ’ s participation in leadership positions by 50% from FY21 32 , 000+ acres brought under sustainable agricultural practices by educating farmers about climate - resilient agricultural practices * As on 31-Dec-25 Environment – Climate change Environment – Energy management Lost Time Injury Frequency Rate (LTIFR) Environment – Water management 0 for permanent employees 0 for contractual workers Reduced Water intensity by ~55% from FY21 Reduced Chemical Oxygen Demand by ~46% from FY21 Key Highlights* ~8 % renewable energy as a share of total electricity consumption vs. FY21 Reduced CO 2 emission intensity by 35%+ from FY21 Environmental Social and Governance • It is based on the S&P Global Corporate Sustainability Assessment (CSA), an independent and rigorous evaluation covering over 13,000 companies globally. • For the 2025 edition, more than 8,551 companies were assessed, and only 540 companies secured a place in the Yearbook, including 32 from India. PI Industries is proud to be among the Top 2 percentile of ESG - rated companies worldwide. • PI ranks among the Top 25 companies globally in the chemical sector and is one of only three Indian chemical companies to be included in the 2025 Yearbook. Score 2024 68 2025 77 Featured in the S&P Global Sustainability Yearbook
Page 12
Creating Tangible, Scalable Societal Impact Aligned with Local Community Needs 12 Health & Hygiene Women Empowerment Education & Skill Development Environment Sustainability Health & wellness support for rural communities • Supporting communities in 6 6 villages in Swasthya Seva Program, 46,500 + beneficiaries reached till Dec - 25 • Supporting 50+ children from underserved communities suffering from congenital heart defects Empowering women through financial inclusion & livelihood Introducing digital learning & smart classes in rural India Promoting Sustainable Farming Practices & Biodiversity Conservation CSR Themes Flagship initiative to build resilient ecosystems to reduce industrial disaster risks & safeguard communities Project Sahyog Supporting farmers on sustainable agriculture practices Project Swasthya Seva - primary healthcare services to the local community Afforestation Program - improving the green cover for the community Centre of Excellence – Industrial Safety & Disaster Risk Management Sustainable Agriculture Local Community Development • Program running in 80 rural villages • 5,000+ women smallholders engaged till Dec - 25 • ~25% increase in income levels through this program • Program supporting 135 schools to improve learning outcomes of children • 7 ,000+ students reached and 1,100+ youth trained • 35,000 + farmers reached till Dec - 25 through Sustainable Agriculture project • ~30,000 trees planted for a significant positive impact on the environment
Page 13
Recognition Reinforces Our Leadership, Safety Culture, and Governance Standards 13 Top 10 Supply Chain Champions Agro Chemical Sector, Institute of Supply Chain Management ( ISCM) Supply Chain Rankings 2025 British Safety Council Sword of Honour – Udaipur Site, October 2025 Most Preferred Workplace 2025 - 26 by Marksmen Daily Rajasthan Business Awards 2025 by The Economic Times India's Top Value Creator 2025 – Agro Chemicals by Dun & Bradstreet Gold Trophy - NSCI Safety Award 2024 for Excellence in Occupational Safety & Health Platinum Award Apex India Safety Excellence Awards 2025 Gold Award At India Green Manufacturing Challenge 2024 for PI Udaipur
Page 14
Long - term growth outlook remains intact... Focused on Margin Discipline, High - Quality Growth and Scaling Strategic Platforms 14 CSM Exports: Technology focused approach to drive incremental business Domestic: Focus on portfolio diversification with high quality revenue Health Science: Building a differentiated play in Pharma C R DMO space Progressing on strategic initiatives in line with plan • Positive outlook driven by good Rabi season • Growing market adoption of new products is driving sustained sales momentum • Biological business on revival mode based on regulatory normalization • Pricing pressure in the generic segment likely to remain elevated • Advance technology platform to unlock new growth opportunities • Commerciali z ation of PI’ s own NCEs; additional leads progressing well with a partnership model • Robust g lobal pipeline of Biological products a cross various development stages • I norganic growth opportunities under evaluation to complement the growth in long - run • Accelerated commercialization of New Products and scaling up of newly launched products to drive sales • Sustained flow of new enquiries supporting future capacity creation through targeted capex investment • On track for sequential growth in Q4 on the back of committed customer offtake plans • Expanding & enhancing GMP site in Lodi, Italy; Non - GMP sites in India • Building relationships with Biotech & Big Pharma through Global Business Development • Improved business development and R&D pipeline visibility over the next 1 - 2 years .. W ith industry upturn in sight, we expect growth momentum to start building from Q4 FY26 ..
Page 15
15 15
Page 16
Agchem Business model built on the principles of respect for IP and established relationships 16 Non conflicting business model … well respected by Global Innovators as Partners • State of the Art R&D facilities o Accredited for GLP and ‘ Norms on OECD Principles ’ by NGCMA • To service its customers • 1 R&D Facility • 5 Manufacturing Sites • Domestic Brand Distribution o 25+ stock points o 15,000+ distributors o 100,000+ retail points • 3 Global locations o Japan for business development activities o China for Sourcing o Germany for Knowledge Management Common Infrastructure Develop knowledge, products, processes and experience in different complex chemistries Cross - Selling Opportunities Custom Synthesis & Manufacturing • Early stages of their life cycles • Complex Chemistries • Process development • IP Protection & Generation IN - LICENSING • Introducing new products, partnering wit h global innovators • Ensure longer product cycles by brand building • Develop solutions for the Indian A g chem Industry with the partnership approach Exports Market Domestic Brand Market Leveraging our Pan India network, demonstrating brand building capabilities and experienced team to deliver in - licensed, branded generics & co - marketed products R&D Partnership • Consistent track record of financial performance Leveraging on chemistry process research and manufacturing capabilities catering to Global Innovators; Partnering for IP Creation. Leading Ag C hem Distribution Company in India with leading market share in certain crops India ’ s largest CRAMS Company with majority revenue from Patented Products SYNERGISTIC APPROACH
Page 17
Differentiated Domestic Distribution Model Driven By Unique Solutions through Global Partnerships, Brands Building Capabilities And Market Reach 17 Farmers & Extensive Distribution Network 25 stock points; 15K+ distributors; 100K+ retail points More than 6 decades creating market - leading brands Significant revenue from Brands ranked No. 1 or 2 in the market, some brands are more than a decade old Strong Pipeline Molecules based on crop solutions and Indian needs FOCUS ON INNOVATION BENEFITS OF CROSS SELLING OPPORTUNITIES PROCURE REPEAT BUSINESS UNDERLYING PRINCIPLES RESPECT & DEVELOP IP REPUTATION OF TRUST & RELIABILITY FORGE RELATIONSHIP • Extension & product development & stewardship (team experience in handling complex new - age premium chemistries) • Strong relationship with stakeholders • Policy level by participation Strong Partner Having experience more than 6 decades 25+ Global Innovators Crop Solutions Channel Enablers Digi - tech @Core Farmers • Crop solution approach focussing farmer & using ICT (Information, Communication and Technology) • Organization structure empowered with digi tech to support and demonstrate value delivery to farmers • Online analytics tools for farmers and employees • I nnovative Ideas and branding for enhancing product life cycle • Experience of successfully managing transition of products from patented to generic • Application services for development & engagement Engagement Efficiency Excellence Evaluation & Trials Domestic Business – Brands Regulatory services & Registrations Marketing & Distribution
Page 18
Multipronged strategy to sustain the growth momentum backed by multiple growth engines & aggressive M&A 18 Prudent capital allocation to ensure the long - term shareholder value creation Market Expansion Creation Segments Operation excellence Brands Inorganic Products Assets Niche vertical with a future Pharma/ Specialty chemical High growth application areas having synergy Disruptive Value added Technologies Build Customer Intimacy Product & Services IP De - risk & Create Inorganic Value creation Organic Grow Smart Deepening our technological capabilities to open new horizons Multiple Growth Engines / Levers • Research and process innovation with global partnerships • Marketing & Distribution - Product Pipeline • Biologicals • Horticulture Specialist • PI Health Sciences - CRDMO De - risk • Manufacturing concentration • New formulation of existing products • Biological Process • Chemistry • Block Builders • Process engineering • Flow Digital • Information integration • Decision tools
Page 19
19 Decades of Transformation Driving Consistent Value Creation Unique approach of partnership with global innovators Leading Agri Distribution player • Diversify into Pharma & global Biologicals space • Geographical expansion : US, LATAM & Europe • Pharma business amongst the Top 5 CRDMO • Global biological leader • New molecules - Bringing innovation to the world • New technologies - Flow, Vapor • Foray into electronics chemicals Years of Disruption Consistent Revenue Growth 1995 2020 2025 ~20% ~20% ~20% Transformation at each stage • First to commence Agchem CSM • Pioneered Biologicals in India • R&D Investment @ INR 250+ Cr per year • Acquisition of Isagro – Horticulture specialist AgSciences - > LifeSciences Top 5 Global CSM player Innovation led Global Conglomerate 1961 Right to win : Strong Balance sheet, Innovation mindset, Global partnership & Execution excellence Reported Revenue CAGR 2030
Page 20
Outshines competitors in delivering business needs of the customers by unlocking value & fearlessly reinventing ourselves An organization that is committed to excellence in whatever it does . . . known for over 2 decades to be the Top wealth creator . . . “ “ A Trusted Brand & Partnerships • 5+ decades of relationship with Global innovator companies • Zero conflicts till date Successful Product Brands & Services • Amongst Top 5 in the world in AgChem CSM • 70% + revenue from proprietary products Addressing Emerging Opportunities • Never a “ me - too ” player • Establishing new frontiers of Agri, Horticulture .. • Biologicals • Health Sciences ESG Anchored • ESG, the way of life • Featured in the S&P Global Sustainability Yearbook 2025 Science & Technology • The only fully integrated R&D with all disciplines under one roof – a global benchmark • Rapid adoption of latest technologies PI: Trusted, Resilient and Future - Ready 20
Page 21
Agchem CSM, a global leader, backed by strong technological strengths 21 Technology pioneer with technological and IP based interventions in global contract manufacturing Product portfolio consists of early stage molecules with continued thrust to adapt sustainable practices 15 Fully automated Multipurpose Plants (MPPs) with Distributed Control System (DCS) spread across 5 locations Capital expenditure underway as per plan with 3 MPPs under construction Extensive experience in handling Hazardous Chemistry with over 130 unit processes Differentiated technologies Flow Technology Vapor Phase Bio technology Largest Commercial Scale Reactions 21
Page 22
World - class R&D set - up delivering innovative and disruptive solutions 22 Ag c hem Labs Pharma Labs R&D State - of - the - art R&D Labs at 4 locations NABL ISO17025 and GLP certified New ICP - OES Addition of UPLC - CAD (Charged Aerosol Detector) 80+ projects a t different development stages 700+ Scientists incl. 200+ Doctorates 250+ Patents t ill date W ith 40 patents in FY26 In - house library with a vast array of knowledge resources 1 st Indian company to innovate "PIOXANILIPROLE ” Now filed for registration
Page 23
40+ Countries 10 Overseas Offices 8 Mfg. Sites 25 Stock Points 4,000+ Employees 100,000+ Retail Points 15,000+ Distributors Dusseldorf Beijing India Tokyo Sao Paulo Amsterdam Milan Our Markets Overseas Offices Raleigh Dubai Seattle St. Louis 2,000+ Contracted employees Our Global Presence 23 Registered Office Corporate Office R&D Manufacturing Units Depots India Strong understanding of international work culture with 60+ years of deep - rooted relationships
Page 24
Demonstrated ability to constantly reinvent itself over 8 Decades Guided by our Values 01 Constantly Differentiating our Business to create Moats with Excellence from Ag distribution to CSM to Innovation in Ag; now to Life Sciences 02 03 05 06 07 World - class Integrated R&D capabilities from discovery to markets: Science & Technology, our Passion Digital Edge From Assets to knowledge, to offer consistency with speed ESG, a Way of Life at PI Top 2 percentile ESG - rated globally; 2 nd consecutive year of S&P CSA yearbook 08 A High - Performance Growth Engine Powering the Next Era of Life Sciences Leadership Demonstrated Wealth Creation with Strong Financials Debt free balance sheet, War chest of growth capital 04 Unique Business Model and Strong Global Relationships with Partners to bring Innovation to Life People First Constantly building, acquiring and growing our Human Talent globally 24
Page 25
Thank You 25